| Aktienanzahl | 14,90 Mio. |
| Aktientyp | Stammaktie |
he NASDAQ Stock Market notified KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), by letter dated November 17, 2015, that the Company is not currently in compliance with Nasdaq’s continued listing requirement set forth in Rule 5250(c)(1) of the Nasdaq Listing Rules (the “Rules”), due to its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (the “2015 Third Quarter 10-Q”) with the Securities and Exchange Commission (the “SEC”).